CAPRISA 004 替诺福韦杀微生物剂试验：替诺福韦凝胶对 HIV 传播瓶颈无影响。
CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.
机构信息
Institute of Infectious Diseases and Molecular Medicine, Division of Medical Virology, University of Cape Town, Cape Town.
出版信息
J Infect Dis. 2012 Jul 1;206(1):35-40. doi: 10.1093/infdis/jis305. Epub 2012 May 2.
Abstract
Alterations of the genital mucosal barrier may influence the number of viruses transmitted from a human immunodeficiency virus-infected source host to the newly infected individual. We used heteroduplex tracking assay and single-genome sequencing to investigate the effect of a tenofovir-based microbicide gel on the transmission bottleneck in women who seroconverted during the CAPRISA 004 microbicide trial. Seventy-seven percent (17 of 22; 95% confidence interval [CI], 56%-90%) of women in the tenofovir gel arm were infected with a single virus compared with 92% (13 of 14; 95% CI, 67%->99%) in the placebo arm (P = .37). Tenofovir gel had no discernable impact on the transmission bottleneck.
摘要
生殖器黏膜屏障的改变可能会影响从感染人类免疫缺陷病毒的源宿主传播到新感染个体的病毒数量。我们使用异源双链追踪分析和单基因组测序来研究基于替诺福韦的杀微生物剂凝胶对在 CAPRISA 004 杀微生物剂试验中发生血清转换的女性传播瓶颈的影响。与安慰剂组（95%置信区间 [CI]，56%-99%）相比，替诺福韦凝胶组中有 77%（22 例中的 17 例；95%CI，56%-90%）的女性感染了单一病毒（P=.37）。替诺福韦凝胶对传播瓶颈没有明显影响。
相似文献
1
CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.CAPRISA 004 替诺福韦杀微生物剂试验：替诺福韦凝胶对 HIV 传播瓶颈无影响。
J Infect Dis. 2012 Jul 1;206(1):35-40. doi: 10.1093/infdis/jis305. Epub 2012 May 2.
2
Adherence in the CAPRISA 004 tenofovir gel microbicide trial.CAPRISA 004替诺福韦凝胶杀微生物剂试验中的依从性。
AIDS Behav. 2014 May;18(5):811-9. doi: 10.1007/s10461-014-0751-x.
3
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.替诺福韦凝胶作为一种抗逆转录病毒的杀微生物剂，用于预防女性感染艾滋病毒的有效性和安全性。
Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19.
4
Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.在CAPRISA 004试验中，依从性干预对替诺福韦凝胶有效性的影响。
AIDS Behav. 2014 May;18(5):841-8. doi: 10.1007/s10461-014-0752-9.
5
No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.在 CAPRISA 004 研究中，替诺福韦杀微生物剂试验中，没有证据表明在突破性感染中选择了增强 gag-蛋白酶或 Nef 功能的 HIV-1。
PLoS One. 2013 Aug 28;8(8):e71758. doi: 10.1371/journal.pone.0071758. eCollection 2013.
6
Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.在CAPRISA 004试验中，生殖器替诺福韦浓度与预防HIV感染相关：坚持用药对杀微生物剂有效性的重要性。
J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):264-9. doi: 10.1097/QAI.0000000000000607.
7
Reformulated tenofovir gel for use as a dual compartment microbicide.重新配方的替诺福韦凝胶，用作双隔室杀微生物剂。
J Antimicrob Chemother. 2012 Sep;67(9):2139-42. doi: 10.1093/jac/dks173. Epub 2012 May 11.
8
Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.替诺福韦凝胶（一种阴道杀菌剂）在南非女性中的安全性：CAPRISA 004试验结果
Antivir Ther. 2013;18(3):301-10. doi: 10.3851/IMP2311. Epub 2012 Aug 23.
9
Topical microbicides for prevention of sexually transmitted infections.用于预防性传播感染的局部用杀微生物剂。
Cochrane Database Syst Rev. 2012 Jun 13(6):CD007961. doi: 10.1002/14651858.CD007961.pub2.
10
A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.一项评估 1%替诺福韦凝胶应用后女性生殖道分泌物和可溶性黏膜免疫中抗 HIV 活性的随机试验。
PLoS One. 2011 Jan 25;6(1):e16475. doi: 10.1371/journal.pone.0016475.
引用本文的文献
1
Impact of Case Definitions on Efficacy Estimation in Clinical Trials-A Proof-of-Principle Based on Historical Examples.病例定义对临床试验疗效评估的影响——基于历史实例的原理验证
Antibiotics (Basel). 2020 Jul 4;9(7):379. doi: 10.3390/antibiotics9070379.
2
Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides.脒基硫酮衍生物作为有效的抗 HIV 和抗单纯疱疹病毒杀微生物剂。
PLoS One. 2018 Jun 5;13(6):e0198478. doi: 10.1371/journal.pone.0198478. eCollection 2018.
3
Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.简短报告：1%替诺福韦凝胶杀微生物剂对具有更高传播潜能的HIV-1变体的选择
J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):43-47. doi: 10.1097/QAI.0000000000001458.
4
Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression.急性感染期病毒的复制能力推动HIV-1疾病进展。
J Virol. 2017 Mar 29;91(8). doi: 10.1128/JVI.01806-16. Print 2017 Apr 15.
5
An Intravaginal Ring for the Simultaneous Delivery of an HIV-1 Maturation Inhibitor and Reverse-Transcriptase Inhibitor for Prophylaxis of HIV Transmission.一种用于同时递送HIV-1成熟抑制剂和逆转录酶抑制剂以预防HIV传播的阴道环。
J Pharm Sci. 2015 Oct;104(10):3426-39. doi: 10.1002/jps.24551. Epub 2015 Jul 6.
6
Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis.在使用抗逆转录病毒暴露前预防药物期间感染艾滋病毒的女性中的抗体成熟情况。
J Infect Dis. 2015 Sep 1;212(5):754-9. doi: 10.1093/infdis/jiv110. Epub 2015 Feb 23.
7
HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.来自CAPRISA 004替诺福韦凝胶暴露前预防试验的血清转化者的HIV疾病进展情况。
J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):55-61. doi: 10.1097/QAI.0000000000000367.
8
Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trial.在一项大型社区随机试验中开发用于横断面 HIV 发病率估计的方法。
PLoS One. 2013 Nov 13;8(11):e78818. doi: 10.1371/journal.pone.0078818. eCollection 2013.
9
Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges.阴道内释放富马酸替诺福韦二吡呋酯的环完全保护猕猴免受多次阴道猴 HIV 挑战。
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16145-50. doi: 10.1073/pnas.1311355110. Epub 2013 Sep 16.
10
No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.在 CAPRISA 004 研究中，替诺福韦杀微生物剂试验中，没有证据表明在突破性感染中选择了增强 gag-蛋白酶或 Nef 功能的 HIV-1。
PLoS One. 2013 Aug 28;8(8):e71758. doi: 10.1371/journal.pone.0071758. eCollection 2013.
本文引用的文献
1
Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys.低剂量黏膜猴免疫缺陷病毒感染可限制恒河猴早期复制动力学和传播的病毒变异株。
J Virol. 2010 Oct;84(19):10406-12. doi: 10.1128/JVI.01155-10. Epub 2010 Aug 4.
2
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.替诺福韦凝胶作为一种抗逆转录病毒的杀微生物剂，用于预防女性感染艾滋病毒的有效性和安全性。
Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19.
3
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men.男男性行为者中 HIV-1 的高多重感染。
PLoS Pathog. 2010 May 13;6(5):e1000890. doi: 10.1371/journal.ppat.1000890.
4
A substantial transmission bottleneck among newly and recently HIV-1-infected injection drug users in St Petersburg, Russia.俄罗斯圣彼得堡新感染和近期感染 HIV-1 的注射吸毒者中存在重大传播瓶颈。
J Infect Dis. 2010 Jun 1;201(11):1697-702. doi: 10.1086/652702.
5
Wide variation in the multiplicity of HIV-1 infection among injection drug users.注射吸毒者中 HIV-1 感染的多重性存在广泛差异。
J Virol. 2010 Jun;84(12):6241-7. doi: 10.1128/JVI.00077-10. Epub 2010 Apr 7.
6
Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants.对1型人类免疫缺陷病毒C亚型感染复数进行定量分析，结果显示传播变异体呈非泊松分布。
J Virol. 2009 Apr;83(8):3556-67. doi: 10.1128/JVI.02132-08. Epub 2009 Feb 4.
7
Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1.炎症性生殖器感染减轻了A和C亚型HIV-1异性传播中的严重基因瓶颈。
PLoS Pathog. 2009 Jan;5(1):e1000274. doi: 10.1371/journal.ppat.1000274. Epub 2009 Jan 23.
8
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.原发性HIV-1感染中传播及早期奠基者病毒包膜的鉴定与特征分析
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7. doi: 10.1073/pnas.0802203105. Epub 2008 May 19.
9
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing.通过单基因组扩增和测序解析1型人类免疫缺陷病毒的传播及早期包膜多样化
J Virol. 2008 Apr;82(8):3952-70. doi: 10.1128/JVI.02660-07. Epub 2008 Feb 6.
10
BEAST: Bayesian evolutionary analysis by sampling trees.BEAST：通过抽样树进行贝叶斯进化分析。
BMC Evol Biol. 2007 Nov 8;7:214. doi: 10.1186/1471-2148-7-214.
Zotero 插件